期刊
PHARMACOLOGY & THERAPEUTICS
卷 95, 期 2, 页码 191-202出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0163-7258(02)00258-9
关键词
endocannabinoids; anandamide; vasorelaxation; endothelium; gap junctions
The prototypic endocannabinoid, anandamide, and synthetic analogues have been shown to elicit pressor and depressor effects, bradycardia, vasorelaxation, and inhibition of neurotransmission in the central and peripheral nervous systems. Cannabinoid-mediated inhibition of neurotransmission is mediated by inhibition of voltage-gated Ca2+ channels and adenylyl cyclase and activation of inwardly rectifying K+ channels. The precise mechanisms underlying the vasorelaxant actions of cannabinoids are currently unclear, but might involve both receptor-dependent and -independent and endothelium-dependent and -independent pathways. Mechanisms proposed have included the release of endothelial autacoids, activation of myoendothelial gap junctions, activation of the Na+ pump, activation of K+ channels, inhibition of Ca2+ channels, and activation of vanilloid receptors, leading to the release of sensory neurotransmitters. Pathophysiologically, the vasodilator actions of endocannabinoids have been implicated in the hypotension associated with both septic and haemorrhagic shock, but their physiological significance remains to be determined. (C) 2002 Elsevier Science Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据